Roche Holding AG (LON:0QQ6)
London · Delayed Price · Currency is GBP · Price in CHF 279.80
-2.40 (-0.85%)
At close: Sep 12, 2025
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
564.35K GBP
Profits / Employee
83.82K GBP
Market Cap
210.51B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| HUTCHMED (China) | 1,811 |
| Genus | 3,500 |
Roche Holding AG News
- 4 days ago - Roche Holding AG (RHHBY) Presents at Goldman Sachs 22nd European Medtech & Healthcare Services Conference - Slideshow - Seeking Alpha
- 10 days ago - Roche Holding AG (RHHBY) Gains CE-IVDR Approval for VENTANA HER2 (4B5) Test | RHHBY stock news - GuruFocus
- 10 days ago - New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or ... - GuruFocus
- 10 days ago - Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify ... - GuruFocus
- 10 days ago - Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients - PRNewsWire
- 10 days ago - New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD) - GlobeNewsWire
- 10 days ago - New Data for Genentech's Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD) - Business Wire
- 10 days ago - Roche gets EU CE mark for its Port Delivery platform containing Susvimo - Seeking Alpha